Today the TSC Alliance® applauds the U.S. Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults and children six years of age or older who have tuberous sclerosis complex (TSC). HYFTOR™, manufactured by Nobelpharma America, LLC, has Orphan Drug Status for this particular indication. …
eTurboNews tala e mo na'o le au fai saofaga. O le lesitala o saʻoloto.
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE
O lo'o fa'aulufale mai iinei Kiliki iinei e lesitala FREE
OA MEA E AVEA MAI LENEI TUSI:
- Fa'atagaga a Food and Drug Administration (FDA's) a le HYFTOR™, o le muamua lea ua fa'amaonia e le FDA le togafitiga fa'apitoa mo facial angiofibromas i tagata matutua ma tamaiti e ono tausaga pe sili atu o lo'o maua i le tuberous sclerosis complex (TSC).
- HYFTOR™, manufactured by Nobelpharma America, LLC, has Orphan Drug Status for this particular indication.
- eTurboNews tala e mo na'o le au fai saofaga.
